Actively Enhancing Cancer Therapy

Developing targeted, low toxicity treatments for primary tumours and metastatic disease

Our Focus

  • Deliver Outstanding Efficacy
  • Significantly Reduce Toxicity
  • Potential to Treat Metastatic Disease
  • Shorter Treatment Timelines
  • Flexible Platform - Tumour Type Agnostic
  • Prime Investment: Positioned For Rapid Growth and Lucrative Returns
Sonotarg Microbubble Cross Section

Precision Delivery Platform

SonoTarg has developed a next-generation therapeutic platform designed to tackle recalcitrant cancers with minimal side effects for patients.

SonoTarg has created a suite of microbubble-based therapeutic products for the targeted treatment of some of the most difficult to treat cancers. The microbubbles are administered intravenously whilst the gentle pressure of targeted ultrasound is used to deliver the drug payload precisely where it is needed.

As the ultrasound interacts with the microbubbles, acoustic and mechanical forces are generated which help to drive the delivered drugs deep into the target tumour. With this targeted, active delivery approach, more drug gets into and kills the cancer, whilst systemic toxicity is kept to a minimum.

Learn more

This Changes Everything

A new approach to cancer therapy

“At SonoTarg we believe that effective cancer treatment should not be at the expense of good quality of life. By combining the power of sonodynamic therapy with targeted, low dose chemotherapy, SonoTarg intends to improve cancer treatment outcomes whilst allowing good health to be maintained during treatment.

We are passionate about the work we do because we believe that this approach has the potential to change the landscape of cancer therapy for the benefit of millions of future cancer patients.”

Professor Mark Taylor, Chief Medical Officer

Realising True Potential...

SonoTarg is Actively Seeking Strategic Partners and Investors

  • MHRA acceptance of our innovative Phase 1 trial design.
  • Approved E.I.S. investment.
  • ST001 (our lead product) granted ILAP status (innovation passport). Orphan Drug designation likely to follow.
  • A suite of additional products using our unique platform technology in development.
  • Our ground breaking research supported by Innovate UK indicates enhancement of immune therapeutics.
  • High ROI, Low Risk: The Perfect Combination For Your Portfolio
For more info, contact:
investors@sonotarg.com

Please remember, all investments carry risk. Only invest what you can afford to lose.